Logo
  • Home
  • AI Agent
  • Annotations
  • Watchlists
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy

  • Get the full experience

    We save the real magic for signed-in users.

Logo
ABVX US​

Abivax S.A. American Depositary Receipt(ABVX US)

$88.01-2.222.46%Ext:$88.87+0.860.98%(Market Closed · 23:51:12 UTC)

Overview

ProfileEntity Structure

Documents

SEC Filings

Financials & Metrics

FinancialsChartingShort InterestEmployees

Abivax S.A. American Depositary Receipt — Company Profile

Abivax S.A., operating as ABIVAX Société Anonyme, is a French pharmaceutical firm focused on the discovery and optimization of therapeutic drugs for inflammatory, infectious, and oncological diseases. A cornerstone of their product pipeline is ABX464, which is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's Disease, and COVID-19. This compound is also being evaluated in Phase IIa studies for rheumatoid arthritis and has successfully completed Phase IIa trials demonstrating viral remission in patients with HIV. Additionally, the company is advancing ABX 196, an immune-boosting candidate, through Phase 1/2 clinical trials targeting hepatocellular cancer. Abivax also conducts research initiatives for conditions like Dengue fever, influenza, and respiratory syncytial virus. The company has secured license agreements with key French scientific bodies, including the National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. Founded in 2013, Abivax S.A. maintains its headquarters in Paris, France.

Sector
Health Care
Industry
Pharmaceuticals
Exchange
UQ
CEO
Marc de Garidel
Headquarters
Paris, I0, FR
IPO Date
Oct 20, 2023
Employees
80
Website
www.abivax.com

Key Metrics

Price
$92.88
Market Cap
$6.82B
Revenue (TTM)
$0.00
Net Income (TTM)
$-117433000.00
EPS (TTM)
-1.47
P/E (TTM)
0.00
P/B (TTM)
18.62
Dividend Yield
0.00%
ROE (TTM)
-32.06%
ROA (TTM)
-25.41%
Operating Margin
0.00%
Beta
3.54

Dividends

Last Dividend
$0.00
Last Yield
0.00%

Summary

Abivax S.A., operating as ABIVAX Société Anonyme, is a French pharmaceutical firm focused on the discovery and optimization of therapeutic drugs for inflammatory, infectious, and oncological diseases. A cornerstone of their product pipeline is ABX464, which is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's Disease, and COVID-19. This compound is also being evaluated in Phase IIa studies for rheumatoid arthritis and has successfully completed Phase IIa trials demonstrating viral remission in patients with HIV. Additionally, the company is advancing ABX 196, an immune-boosting candidate, through Phase 1/2 clinical trials targeting hepatocellular cancer. Abivax also conducts research initiatives for conditions like Dengue fever, influenza, and respiratory syncytial virus. The company has secured license agreements with key French scientific bodies, including the National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. Founded in 2013, Abivax S.A. maintains its headquarters in Paris, France.

Website
www.abivax.com
Location
Paris, I0, FR
Phone33 1 53 83 08 41
Employees80
CEOMarc de Garidel
Sector
Health Care
Industry
Pharmaceuticals
IPO DateOct 20, 2023

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.

Latest Documents

SEC Filings(99)

Expand
  • F-6EFEffective registration statement (depository shares)21 Sep
  • 6-KCurrent report (foreign private issuer)21 Sep
  • SC 13G/AAbivax S.A.14 Aug
  • SC 13G/AAbivax S.A.13 Aug
  • SC 13D/AAbivax S.A.6 Jul
  • 6-KCurrent report (foreign private issuer)2 Jul
  • 424B5Prospectus filing (Rule 424(b)(5))2 Jul
  • FWPFree writing prospectus1 Jul
  • FWPFree writing prospectus30 Jun
  • 424B5Prospectus filing (Rule 424(b)(5))30 Jun
  • POSASRPost-effective amendment (automatic shelf)30 Jun
  • 6-KCurrent report (foreign private issuer)29 Jun
  • 6-KCurrent report (foreign private issuer)2 Jun
  • 6-KCurrent report (foreign private issuer)22 May
  • 6-KCurrent report (foreign private issuer)20 May
  • SC 13D/AAbivax S.A.11 May
  • 6-KCurrent report (foreign private issuer)7 May
  • 424B7Prospectus filing (Rule 424(b)(7))7 May
  • 6-KCurrent report (foreign private issuer)20 Apr
  • S-8Registration statement (employee benefit plan)23 Mar

News

  • Cedar Grove Capital Q3 2026 Portfolio Update7 Oct
  • Abivax: Priced Right Ahead Of 2 Make-Or-Break Catalysts23 Sep
  • These Analysts Slash Their Forecasts On Abivax Following H1 Results22 Sep
  • Abivax Presents Business Updates and First Half 2026 Financial Results21 Sep
  • Abivax SA Sponsored ADR (NASDAQ:ABVX) Given Average Rating of “Moderate Buy” by Brokerages21 Sep
  • Accenture, Abivax and 3 Stocks to Watch Heading Into Monday21 Sep
  • 4 Biotech Stocks to Watch as Potential Takeover Targets18 Sep
  • Abivax Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call14 Sep
  • Abivax SA Sponsored ADR (ABVX) Upgraded to Buy: Here's Why8 Sep
  • Abivax SA Sponsored ADR (NASDAQ:ABVX) Given Average Recommendation of “Moderate Buy” by Brokerages27 Aug

Mentions in Filings

  • … as been evaluated in patients as a component of indigo naturalis and is an endogenously produced molecule. We are aware of several other parties developing drugs with AhR activity in inflammatory bowel disease, including <strong>Abivax</strong>, Equillium and Dr. Falk Pharma (in partnership with AllianThera Biopharma). Abivax is developing obefazimod, an orally administered, medium-potency systemic AhR agonist that induces upregulation of MiR-124. Obefazimod ha …
    ADIAL PHARMACEUTICALS, INC.Abivax S.A. American Depositary Receipt·10-Q/A - AMENDMENT NO. 1 TO FORM 10-Q Q2·Q2 26·20 Oct
  • … igational agents; includes golimumab, etrasimod, ustekinumab, rosnilimab, MORF-057, PN-943, infliximab, icotrokinra, TYK2 inhibitor, adalimumab, and etrolizumab. Sources: Lancet Gastroenterol Hepatol 2022;7(11):1024–1035; <strong>Abivax</strong> corporate presentation, March 2023; Abivax phase 3 topline readout, July 2025; obefazimod UEG Week presentation, October 2025; Clin Gastroenterol Hepatol 2026;24(2):525–534; Spyre SKYLINE Part A induction results, April 2 …
    Odyssey Therapeutics, Inc.Abivax S.A. American Depositary Receipt·EX-99.2 - 8-K - Regulation FD Disclosure·Q4 26·20 Oct
  • … y companies through successful public listings, including Upstream Bio (NASDAQ: UPB), Structure Therapeutics (NASDAQ: GPCR), LB Pharma (NASDAQ:LBRX), Aktis (NASDAQ: AKTS), CG Oncology (NASDAQ: CGON), RayzeBio (NASDAQ:RYZB), among others. TCGX has also made a number of notable public company investments, including <strong>Abivax</strong> (NASDAQ: ABVX), Tango (NASDAQ: TNGX), and Cogent (NASDAQ: COGT). Our Management Team and Board of Directors Executive Officers
    TCGX Acquisition Corp. IIAbivax S.A. American Depositary Receipt·424B4 - Prospectus filing (Rule 424(b)(4))·Q4 26·16 Oct
  • 1 Aardvark Therapeutics Appoints Clinical Development Leader David Zhang, Ph.D., MBA, to its Board of Directors Brings more than 25 years of experience in clinical strategy, biostatistics and regulatory submissions from <strong>Abivax</strong>, Alumis, MyoKardia and Genentech/Roche SAN DIEGO, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark or the Company) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing n …
    Aardvark Therapeutics, Inc.Abivax S.A. American Depositary Receipt·EX-99.1 - 8-K - Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers·Q4 26·8 Oct
  • Dr. Zhang, age 58, has over 25 years of experience designing clinical programs, analyzing pivotal trial data and supporting regulatory submissions. He has served as the Chief Strategy Officer of <strong>Abivax S.A.</strong>, a clinical-stage biotechnology company focused on therapeutics for chronic inflammatory diseases, since July 2024. At Abivax S.A., he is a member of the Executive Committee and has overseen biometrics, regulatory affairs, quality assurance an …
    Aardvark Therapeutics, Inc.Abivax S.A. American Depositary Receipt·8-K - Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers·Q4 26·8 Oct
  • … y companies through successful public listings, including Upstream Bio (NASDAQ: UPB), Structure Therapeutics (NASDAQ: GPCR), LB Pharma (NASDAQ:LBRX), Aktis (NASDAQ: AKTS), CG Oncology (NASDAQ: CGON), RayzeBio (NASDAQ:RYZB), among others. TCGX has also made a number of notable public company investments, including <strong>Abivax</strong> (NASDAQ: ABVX), Tango (NASDAQ: TNGX), and Cogent (NASDAQ: COGT). Our Management Team and Board of Directors Executive Officers
    TCGX Acquisition Corp. IIAbivax S.A. American Depositary Receipt·S-1 - Registration statement (general form)·Q3 26·25 Sep

Key Stats

Trading

Px/Chg 1D$92.88 / -2.33%
Prev Close$114.79
% of 52Wk H79.92%
Avg Volume1.52M
Beta3.54
Mkt Cap6.82B
FD Mkt Cap8.73B

Float

Shrs Out/Float73.43M / 67.11M
Short Float0.07%
Days to Cover1.45
Stock Repurchased$0.00

Current Valuation

EV6.43B
EV/EBITDA0.00
EV/Sales0.00
P/B18.62
P/S0.00
FCF Yield-0.76%
ROE-32.06%
ROA-25.41%
Current Ratio5.97

Estimates

P/E0.00
Est P/EN/A
Est EPSN/A
Est PEGN/A

Valuation

Metric5Yr AvgJun '24Sep '25Sep '26Oct '26
PRICE-BASED RATIOS
Price / Earnings-29.79-3.85-31.49-26.81-56.99
Price / Sales0.000.000.000.000.00
Price / Book Value43.722.90136.7516.9518.27
Price / Free Cash Flow-69.55-5.68-35.87-108.22-128.44
ENTERPRISE VALUE METRICS
Enterprise Value4,856.6375.45,503.17,242.86,305.2
Enterprise Value / Sales0.000.000.000.000.00
Enterprise Value / EBITDA-29.11-2.82-33.82-28.29-51.51
Enterprise Value / EBIT-28.99-2.80-33.59-28.20-51.35

Financials

Full Financials
Millions EUR5Yr CAGR (%)Dec '21Dec '22Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue—-----
Gross Income—-45.5-50.8---
EBITDA67.1%-38.6-53.3-133.2-162.7-300.7
EBIT66.9%-38.9-53.8-133.9-163.8-301.8
Net Income67.7%-42.5-60.7-147.7-176.2-336.1
EPS (Diluted)14%-2.75-3.18-3.43-2.80-4.65
BALANCE SHEET
Cash & ST Inv71.9%60.727.0261.0144.2530.2
Total Assets52.1%109.275.5327.1205.2584.1
Total Liabilities11.6%83.368.4131.1164.6129.1
Total Shareholder Equity104.7%25.97.2196.040.6455.0
CASH FLOW
Net Operating Cash Flow35.9%-45.7-53.9-100.0-154.1-155.7
Cap Ex-46.3%-1.6-0.3-0.3-0.6-0.1
Free Cash Flow34.7%-47.3-54.3-100.3-154.7-155.8

Enterprise Value Bridge

Millions EUR23 Oct '26
Price (As of 23 Oct '26)87.88
Basic Shares73.43
Market Cap6,453.3
Diluted Shares79.65
Fully Diluted Shares Outstanding79.65
Fully Diluted Market Cap6,999.5
+Consolidated Debt1.2
−In-the-Money Convertible Debt—
+Capital Leases1.2
+Operating Leases—
−Cash & Equivalents-388.0
−Short-term Investments-22.7
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest-
+Pension Liabilities—
Enterprise Value6,066.5

Related companies

Eli Lilly and Company

LLY US

Johnson & Johnson

JNJ US

AbbVie Inc.

ABBV US

Merck & Co., Inc.

MRK US

Novartis Ag

NVS US

Astrazeneca Plc

AZN US

Abbott Laboratories

ABT US

Novo Nordisk A/S

NVO US

Pfizer Inc

PFE US

Vertex Pharmaceuticals Inc / Ma

VRTX US

Bristol Myers Squibb Company

BMY US

Csl Ltd

CSLLY US